Tecan Group AG stock (CH0012100191): Lab automation leader eyes US growth

Tecan Group AG recently collaborated with Singular Genomics Systems, Inc., a US-based firm, to develop customized reagent kits for next-generation sequencing (NGS) library preparation. The partnership, announced in July 2025, targets enhanced automation in genomics workflows, according to MarketsandMarkets as of July 2025. Tecan shares trade on the SIX Swiss Exchange under ticker TECN.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Tecan Group AG: core business model

Tecan Group AG develops and manufactures laboratory automation solutions for life sciences, diagnostics, and biopharma. Its platforms enable high-throughput screening, genomics, and drug discovery, serving academic, biotech, and pharmaceutical customers worldwide. The company reported strong positioning in automated liquid handling, a key segment per industry analyses.

Headquartered in Switzerland, Tecan operates globally with significant US exposure through sales and partnerships. Its OEM business supplies components to major diagnostics firms, contributing to diversified revenue streams.

Main revenue and product drivers for Tecan Group AG

Tecan's revenue stems primarily from its Life Sciences and Partnering Business segments. Liquid handling workstations like the Fluent and Freedom platforms drive demand in research automation. In diagnostics, OEM partnerships provide steady income, with the US market representing a core growth area for US investors tracking medtech innovation.

The July 2025 collaboration with Singular Genomics underscores Tecan's role in NGS workflows, aligning with rising US demand for decentralized testing and personalized medicine, as noted in IndexBox market outlook.

Industry trends and competitive position

The lab automation market is projected to expand through 2031, fueled by AI integration and high-throughput needs in genomics. Tecan competes with Thermo Fisher Scientific, Danaher, and Agilent, holding leadership in liquid handling per MarketsandMarkets evaluations. Its focus on modular systems differentiates it in a fragmented sector.

For US investors, Tecan's exposure to American biotech hubs like Boston and San Francisco offers indirect play on US life sciences R&D spending, which tops global charts.

Why Tecan Group AG matters for US investors

Listed on the SIX Swiss Exchange, Tecan provides US retail investors access via ADRs or international brokers to Europe's medtech strength. With US collaborations like Singular Genomics and presence in diagnostics CDMOs, it ties into American trends in precision medicine and outsourced manufacturing.

Conclusion

Tecan Group AG continues to leverage its automation expertise amid lab digitization trends, with recent US partnerships highlighting growth potential. While market competition persists, its diversified segments and global footprint support ongoing relevance. Investors should monitor upcoming earnings for updates on NGS and diagnostics momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.